Ad hoc: Interim report about clinical trial of BF-200 ALA in actinic keratosis
... LEVERKUSEN, Germany, 30 April 2007 - biofrontera AG announced that an interim report regarding the ...zed the clinical results 12 weeks after treatment. biofrontera expects this second report within few weeks. ...plete analysis of the 12-week data. On this basis, biofrontera intends to continue the further development of the...Biofrontera | Ad-hoc: January 14, 2009
Biofrontera.com ... Leverkusen, 14 January 2009 – Biofrontera AG (ISIN: DE 0006046113) has placed a ... Biofrontera AG. Hemmelrather Weg 201, 51377 Leverkusen, ...Article: Biofrontera Wins Grant - Pharmaceutical Technology Europe
Register today for a free trial, credit card req'd. Find Pharmaceutical Technology Europe articles plus many other academic journal articles, magazine articles & news...Biofrontera AG - Company Profile - BioCentury
Biofrontera's detailed financials; Comprehensive pipeline breakdown, including ... www.biofrontera.com. Development Status. Phase III (05/13/2009) Archive ...Biofrontera</b> Strengthens Its Dermatology Drug Pipeline By Acquiring ...
http://www.biofrontera.com